That all being said, I think with such a strong core competency in nucleosides, nucleotide prodrugs, liver targeting, we do spend some time thinking about where else we could apply this expertise. And clearly in the virology space there are, I think, some easy follow-ons. But we don’t have much bandwidth for thinking about that until we get HCV right.Read the rest of this transcript for free on seekingalpha.com
Idenix Pharmaceuticals' CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.